Ledipasvir (GS5885)

Catalog No.S7579

For research use only.

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

Ledipasvir (GS5885) Chemical Structure

CAS No. 1256388-51-8

Selleck's Ledipasvir (GS5885) has been cited by 7 Publications

1 Customer Review

Purity & Quality Control

Choose Selective HCV Protease Inhibitors

Other HCV Protease Products

Biological Activity

Description Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Targets
HCV [1]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(112.48 mM)
Ethanol 100 mg/mL
(112.48 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 889.0
Formula

C49H54F2N8O6

CAS No. 1256388-51-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03903185 Unknown status Drug: Ledipasvir / Sofosbuvir Oral Product Hepatitis C Chronic|Hematologic Malignancy Ain Shams University|Cairo University March 1 2019 Phase 1|Phase 2
NCT03639207 Withdrawn -- Hepatitis C Virus National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 15 2018 --
NCT05091008 Completed Drug: Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet Hepatitis C Chronic Mansoura University Children Hospital March 1 2018 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ledipasvir (GS5885) | Ledipasvir (GS5885) supplier | purchase Ledipasvir (GS5885) | Ledipasvir (GS5885) cost | Ledipasvir (GS5885) manufacturer | order Ledipasvir (GS5885) | Ledipasvir (GS5885) distributor